Roth Capital Partners doubled its price target for Juniper Pharmaceuticals (NASDAQ:JNP) to $24 from $12 after the company reported 2017 results. The stock closed at $10 on March 9.Read More
Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the indication of luteal phase supplementation in assisted reproductive treatment.
“This approval further expands the global Crinone progesterone gel franchise into the world’s’ third largest pharmaceutical market, giving women and couples struggling with infertility in Japan a new, patient-friendly therapeutic option for luteal phase support,” Frank Condella, CEO of Juniper, said in a statement. “We look forward to supporting the launch of OneCrinone in Japan later this year.”Read More